|
Welcome to Issue 5 of InSite in which you will find details on new guidelines published by the International Myeloma Working Group. If you would like to contribute to the Healthcare Professional Viewpoint section then please get in touch.
Kind regards |
|
2009 Issue 5 |
|
In recent months there have been 2 other publications of note:
Quantitation of serum free light chains in combination with protein electrophoresis and clinical information for diagnosing multiple myeloma in a general hospital population. Piehler, A. P., et al. Clin Chem, 2008. 54(11): p. 1823-30.
Piehler et al. evaluate an approach for laboratory diagnosis of monoclonal gammopathies based on serum protein electrophoresis, serum FLC tests and other clinical and biochemical information. Serum FLCs were only requested when SPE or clinical or other biochemical findings suggested monoclonal gammopathy. This strategy enabled a 75% reduction in the number of serum FLC tests required but still allowed efficient diagnosis of monoclonal gammopathies. Click here to order your copy (Code MKG486).
‘Light chain escape-multiple myeloma’- an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. Kuhnemund, A. et al, J Cancer Res Clin Oncol, 2008. doi 10.1007/s00432-008-0470-7
This report summarises the largest case series of 10 multiple myeloma patients who developed light chain escape at disease relapse. The authors conclude that the early detection of light chain escape through serial serum FLC measurements may prevent the occurrence of unnecessary complications, such as renal impairment or symptomatic bone lesions. Click here to order your copy (Code MKG487). |
|
Publication review – keep up to date with recent publications |
|
Exhibitions and Meetings - Catching up and planning ahead |
|
If you have a friend or colleague who you feel would benefit from receiving this newsletter then please forward this to them.
Received this from a colleague? We need your permission to send you future issues - please Click here to register. |
|
Refer a friend/colleague |
|
The Binding Site Ltd |
|
Þ Presentations from Biennial 2008 Conference in Bath, UK Þ Review of conferences |
|
What’s in Issue 6 |
|
Spotlight Review. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders Dispenzieri et al Leukemia (2008) e Publication 20 November 2008 View the abstract online at http://www.nature.com/leu/journal/vaop/ncurrent/abs/leu2008307a.html
The key recommendations are:-
1. ‘The serum FLC assay in combination with serum PEL and serum IFE is sufficient to screen for pathological monoclonal plasmaproliferative disorders other than AL which requires all the serum tests as well as 24 h urine IFE.’ 2. ‘The serum FLC assay should be measured at diagnosis for all patients with MGUS, smoldering or active multiple myeloma. Solitary plasmacytoma and AL amyloidosis.’ 3. ‘Serial FLC ascertainment should be routinely performed in patients with AL amyloidosis and multiple myeloma patients with oligosecretory disease.’ 4. ‘It should also be done in all patients who have achieved a CR to determine whether they have attained a stringent CR.’
Reprints will be available from Binding Site in January 2009 - Click here to order your copy (Code MKG492). |
|
New guidelines now available |
|
A number of posters featuring Hevylite have now been presented at a variety of meetings including EHA, AACC and ASH. They provide useful information on what this new assay can offer and have stimulated good clinical and scientific discussion. If you have not been able to attend these conferences and view the posters you can find them here. |
|
Don’t forget to visit our webinars page regularly to view webinars held in the USA by Binding Site Inc. We have recently added a webinar entitled: Strategies for Optimizing Outcomes in Myeloma and Other Monoclonal Gammopathies, presented by Dr Maurizio Zangari, Professor of Hematology and Oncology, and Director of Experimental Therapeutics at the University of Utah School of Medicine. |
|
Webinars |
|
Healthcare professional viewpoint |
|
Brian Durie, MD, the Senior Advisor for Hematologic Malignancies and National Program Director for Multiple Myeloma at Aptium Oncology.
"What has been amazing is that as I started to get the Freelite testing on all of my patients I realized that it is remarkably helpful, both for assessing response as well as in some of the other categories of potential utility such as early diagnosis, and evaluation of prognosis." |
|
Renal Week http://www.asn-online.org/education_and_meetings/renal_week/ 4-9 November 2008 Philadelphia, US
Didn't make it to the meeting? No problem. Renal Week 2008 media files are available now at the ASN Conference Media Store. Browse through or search the sessions from the entire Renal Week 2008 meeting. The store includes DVDs, Audio CDs, MP3 Discs, and direct download of MP3 files You may also wish to review some of the posters defended at this meeting. |
|
ASH http://www.hematology.org/meetings/2008/index.cfm 6-9 December 2008, San Francisco UK.
Review an interesting study on serum free light chain testing in CLL. |
|
Next key meetings: 12th International Workshop on Myeloma 26 February - 1 March 2009, PLEASE NOTE: This meeting has been moved to Washington, DC, USA from India. Updated information can be found at: http://www.mw-delhi09.com See you there. |
|
International Marketing Manager - Freelite™ & Hevylite™ |
|
Find out more about serum free light chains at www.freelite.co.uk |
|
If you no longer wish to receive this newsletter, please Click here to unsubscribe. |
|
Having problems viewing or printing this newsletter? Click here to view online. Previous editions of InSite |
|
can also be read online here. |
|
Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Hutchison, C.A., et al., Clin J Am Soc Nephrol, 2008. 3(6): p. 1684-90.
This study describes for the first time polyclonal serum FLC (free light chains) in patients with chronic kidney disease. Serum concentrations of both kappa and lambda FLCs increased with worsening renal function. Due to the loss of preferential glomerular filtration of kappa FLC monomers over lambda dimers with renal impairment, the median FLC ratio increased with decreasing renal function. Please request your copy from your local office mentioning code MKG491.
Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. Hutchison, C. A. et al, BMC Nephrol, 2008. 9(1): p.11. doi 10.1186/1471-2369 9-11
This study examines the diagnostic utility of serum FLC in the management of patients with dialysis-dependent acute renal failure. Use of a modified range for the FLC κ/λ ratio (0.37 – 3.1) increased the diagnostic specificity of the serum FLC assay with no loss of diagnostic sensitivity, allowing rapid identification of Multiple Myeloma as the underlying cause of acute renal failure. Click here to order your copy (Code MKG493). |
|
Freelite in Renal Disease |
|
Hevylite™ - Early Publications |
|
EHA 14th Congress 4-7 June Berlin, Germany http://eha.eurocongres.com/14th/ Abstract deadline 1st March 2009 - Submit here |
|
Euromedlab 7-11 June 2009, Innsbruck, Austria Abstract deadline 20th February 2009 – Submit here Please visit our workshop at Euromedlab - More details in Issue 6 |
